Clinical Trial Update: Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating octreotide to prevent or reduce diarrhea in patients undergoing chemoradiotherapy for anal or rectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer
• Colorectal Cancer
• Radiation Enteritis
• Rectal Cancer

Drugs mentioned

• OCTREOTIDE (OCTREOTIDE ACETATE)

Snippet

Sponsor: Radiation Therapy Oncology Group | Conditions: Anal Cancer, Colorectal Cancer | Phase 3 | Status: COMPLETED